Inozyme Pharma, Inc. (INZY)

Jul 1, 2025 - INZY was delisted (reason: acquired by BMRN)

4.000

0.00 (0.00%)

Inactive · Last trade price on Jun 30, 2025

Inozyme Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-106.72	-102.02	-71.17	-67.06	-56.62	-56.42
Depreciation & Amortization	0.74	0.74	0.83	0.74	0.67	0.22
Loss (Gain) From Sale of Assets	-	-	0.02	0.02	-	-
Asset Writedown & Restructuring Costs	-	-	-	-	-	17.76
Loss (Gain) From Sale of Investments	-3.61	-5.04	-5.44	-1.67	0.17	0.28
Stock-Based Compensation	8.11	7.95	7.04	7.67	7.16	2.31
Other Operating Activities	1.84	1.76	1.12	0.53	0.38	-
Change in Accounts Payable	1.5	1.36	-1.38	0.15	-0.68	2.1
Change in Other Net Operating Assets	1.62	3.35	-1.7	1.86	0.76	-2.21
Operating Cash Flow	-96.52	-91.91	-70.68	-57.76	-48.15	-35.97
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Capital Expenditures	-0.03	-0.06	-0.3	-0.41	-0.4	-0.57
Investment in Securities	90.32	67.06	-53.35	-4.99	43.19	-116.61
Investing Cash Flow	90.29	67	-53.65	-5.4	42.8	-117.18

Financing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Long-Term Debt Issued	-	-	40	4.05	-	-
Net Debt Issued (Repaid)	-	-	40	4.05	-	-
Issuance of Common Stock	11.47	11.4	85.97	68.74	0.61	116.17
Financing Cash Flow	11.47	11.4	125.97	72.79	0.61	149.81

Net Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Foreign Exchange Rate Adjustments	-0	0	-0.02	-0.03	0.02	-
Net Cash Flow	5.23	-13.51	1.63	9.6	-4.72	-3.34

Free Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Free Cash Flow	-96.55	-91.97	-70.97	-58.17	-48.55	-36.54
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-1.52	-1.46	-1.37	-1.54	-2.06	-3.31
Levered Free Cash Flow	-56.38	-55.09	-46.05	-32.07	-27.29	-29.91
Unlevered Free Cash Flow	-52.85	-51.61	-43.96	-31.9	-27.29	-29.91

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash Interest Paid	4.35	4.35	2.35	0.17	-	-

SEC Filings: 10-K · 10-Q